Biologická léčba v onkologii (II)
Monoklonální protilátky, cytokiny

Česká verzia

Authors: P. Králíčková; J. Krejsek; I. Krčmová
Authors place of work: ÚSTAV KLINICKÉ IMUNOLOGIE A ALERGOLOGIE ; Přednosta: prof. RNDr. Jan Krejsek, CSc. ; Fakultní nemocnice Hradec Králové
Published in the journal: Prakt. Lék. 2011; 91(5): 258-262
Category: Reviews

Summary

Biological treatment has become an integral part of complex anticancer therapy in recent years. Monoclonal antibodies (either alone or conjugated with drug or a radionuclide) and cytokines are frequently used in clinical practice. Our article provides a review of the manufacture, mechanisms of action, indications and side effects of monoclonal antibodies and cytokines.

Key words:
biological treatment, monoclonal antibodies, cytokines.

Zdroje

1. Bellmunt, J. Current treatment in advanced renal cell carcinoma (RCC): impact of target therapies in management of RCC. Eur. Urol. 2007, 6, p. 484-491.

2. Bellone, M., Mondino, A., Corti, A. Vascular targeting, chemotherapy and active immunotherapy:teaming up to attack cancer. Trends Immunol. 2008, 29(5), p. 235-241.

3. Bubeník, J., Mikyšková, R., Vonka, V. et al. Interleukin-2 and dendritic cells as adjuvans for surgical therapy of tumours associated with human papillomavirus type 16. Vaccine 2003, 21(9-10), p. 891-896.

4. Cortes, J., Rousselot, P., Kim, DW. et al. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or –intolerant chronic myeoid leukemia in blast crisis. Blood 2007, 109(8), p. 3207-3213.

5. Congy-Jolivet, N. Probst, A. Watier, H. et al. Recombinant therapeutic monoclonal antibodies: Mechanisms of action in relation to structural and functional duality. Crit. Rev. Oncol. Hematol. 2007, 64(3), p. 226-233.

6. Cwiertka, K., Trojanec, R., Špašková, K., Hajdúch, M. Terapeutické monoklonální protilátky v onkologii. Klin. Farmakol. Farm. 2004, 21(3), s. 165-170.

7. Dassonville, O., Bozec, A., Fischel, J.L. et al. EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences. Crit. Rev. Oncol. Hematol. 2007, 62, p. 53-61.

8. Eskens, A.L.M., Verweij, J. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors. Rev. Eur. J. Cancer 2006, 42(16), p. 3127-3139.

9. Escudier, B., Farace, F., Angevin, E. et al. Immunotherapy with IL-2 and lymphokine-activated natural killer cells: Improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL-2. Eur. J. Cancer 1994, 30(8), p. 1078-1083

10. Gerein, V., Rastorguev, E., Gerein, J. et al. Use of interferon- alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann. Otol. Rhinol. Laryngol. 2005, 14(6), p. 463-471.

11. Gregoire, M., Ligeza-Poisson, C., Juge-Morineau, N., Spisek, R. Anti-cancer therapy using dendritic cells and apoptotic tumour cells: pre-clinical data in human mesothelioma and acute myloid leukemia. Vaccine 2003, 21(7-8), p. 791-794.

12. Hájek, R., Maisnar, V., Krejčí, M. Thalidomid. Klin. Farmakol. Farm. 2005, 19(1), s. 43-46.

13. Hořejší, V., Bartůňková, J. Základy imunologie. 3. vydání, Praha: Triton, 2005, s. 40, 106-118, 128-144, 174-182.

14. Hurwitz, H., Saini, S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin. Oncol. 2006, 33(10), p. 26-34.

15. Klener, P. a kol. Klinická onkologie. 1. vydání, Praha: Galén, 2002, s. 223-225.

16. Klener, P. Klener, P. ml. Nová protinádorová léčiva a léčebné strategie v onkologii. 1. vydání, Praha: Grada, 2010, s. 77-84, 157-190.

17. Krajsová, I. Kožní projevy cílené léčby nádorů. Remedia 2006, 16(4), s. 416-420.

18. Krčmová, I. Omalizumab – terapeutická perspektiva v léčbě těžkého bronchiálního astmatu. Remedia 2006, 16(4), s. 4308-4442.

19. Motzer, R.J., Rakhit, A., Thompson, J.A. et el. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon –α2a for patients with advanced renal cell carcinoma. J. Interferon. Cytokine. Res. 2001, 21(4), p. 254-263.

20. Pilz, G., Wipfler, P., Ladurner, G., Kraus, J. Modern multiple sclerosis treatment – what is approved, what is on the horizon. Drug. Discov. Today 2008, 13(23/24), p. 1013-1025.

21. Prenen, H., Gil, T., Awada, A. New therapeutic developments in renal cell cancer. Crit. Rev. Oncol. Hematol. 2009, 69(1), p.56-63.

22. Ravaud, A., Wallerand, H., Culine, S. et al. Update the medical treatment of metastatic renal cell carcinoma. Eur. Urol. 2008, 54(2), p. 315-325.

23. Sharkey, R.M., Goldenberg, D.M. Use of antibodies and immunoconjugates for the therapy of more accesible cancer. Adv. Drug Deliv. Rev. 2008, 60(12), p. 1407-1420.

24. Sobotková, M., Bartůňková, J. Monoklonální protilátky a další biologická léčiva užívaná v imunosupresivní léčbě. Remedia 2008, 5, p. 356-364.

25. Stern, M., Herrmann, R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit. Rev. Oncol. Hematol. 2005, 54, p. 11-29.

26. Stueve, O. The effect of natalizumab on the innate and adaptive immune system in the central nervous system. J. Neurol. Sci. 2008, 274(1-2), p. 39-41.

27. Swann, P.G.,Tolnay, M., Muthukkumar, S. et al. Consideration for the development of therapeutic monoclonal antibodies. Curr. Opin. Immunol. 2008, 20(4), p. 1-7.

28. Špička, I., Kleibel, Z., Hájek, R. Bortezomib. Remedia 2005, 15(3), s. 196-204.

29. Špinarová, L., Vítovec, J. Kombinovaná léčba po transplantaci srdce. Remedia 2006, 16(3), s. 168-273.

30. Vencovský, J. Abatacept v léčbě revmatoidní artritidy. Remedia 2007, 17(6), s. 455-463.

29. Widakowich, Ch., de Azambuja, E., Gil, T. et al. Molecular targeted therapies in breast cancer: Where are we now? Int. J. Biochem. Cell. Biol. 2007, 39(7-8), p. 1375-1387.

31. Zbořil, V. Infliximab v klinické léčebné praxi. Klin. Farmakol. Farm. 2005, 19(1), s. 67-71.